Diligence memo · auto-generated · as of July 2, 2026
HeMemics Biotechnologies, Inc.
HeMemics Biotechnologies, Inc. looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
HeMemics Biotechnologies, Inc. operates in Biotechnology, based in ROCKVILLE.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
HeMemics Biotechnologies, Inc. has raised $877K in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $777K on 2018-04-07.
Most recent recorded round closed around 2020-12-07.
Valuation (modeled)modeled
Provath models HeMemics Biotechnologies, Inc. at approximately $4.2M (range $53K–$42M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.27× the median modeled value of Pre-Seed Biotechnology companies in 2019–2021 (156 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 32 months.
Last raise 5.6 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round was 7.8× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 16% of Biotechnology peers (4293 compared).
Modeled value ranks above 9% of those peers.
Closest niche peers: Crimson BioPharm Inc., Pinpoint Therapeutics Inc., Transplant Logistics & Informatics Llc, RNAissance AG LLC, Pylum Biosciences, Inc..
Peoplefiled
13 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.